A Phase 1 Study to Assess the Safety and Antiviral Activity of PEG-rIL-29 Administered as a Single Agent and in Combination With Ribavirin in Treatment-Relapsed and Treatment-Naive Subjects With Chronic Hepatitis C Virus Infection
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2009
At a glance
- Drugs Peginterferon lambda-1a; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors ZymoGenetics
- 31 Aug 2018 Biomarkers information updated
- 09 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Oct 2009 Results will be presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), held in Boston, Massachusetts from 30 Oct 2009 to 3 Nov 2009.